Adimab granted Novo Nordisk a non-exclusive license to use Adimab's technology to discover antibody-based therapeutics against an unlimited number of targets

Adimab LLC

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Novo Nordisk A/S

Denmark / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced